Generic alternative to EpiPen released amid allergy treatment shortage

(By Alia Paavola for Becker’s Hospital Review)

Sandoz, a generics and biosimilar unit of Novartis, will make its generic epinephrine shots immediately available for sale in U.S. retail pharmacies as a shortage of Mylan’s lifesaving allergy treatment EpiPen drags on.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.

Leave a Reply